Anxious to fight off Pfizer’s $106 billion marriage proposal, AstraZeneca’s research team has rushed its high-profile immuno-oncology drug into a late-stage test. And they’re setting out by targeting non-small cell lung cancer in the first Phase III in the MEDI4736 program. …read more

Source: AstraZeneca rushes immuno-oncology star into PhIII lung cancer study


0 No comments